Treatment of Cushing's syndrome with the long-acting somatostatin analogue SMS 201-995 (Sandostatin)

C. Invitti, M. De Martin, A. Brunani, M. Piolini, F. Cavagnini

Research output: Contribution to journalArticle

Abstract

Three patients with Cushing's disease and one patient with paraneoplastic hypercortisolism were treated for 24-49 days with the long-acting analogue of somatostatin, SMS 201-995, Sandoz (SMS), administered in increasing doses up to 400-1200 μg daily. In the three Cushing's patients during SMS treatment plasma ACTH displayed an initial rise and a subsequent decrease. The pattern of urinary free cortisol (UFC) tended to be opposite to that of ACTH. In one of these patients, UFC continued to decrease throughout the treatment, without becoming normal. In the patient with paraneoplastic hypercortisolism, SMS was associated with a progressive decrease, though not the normalization, of UFC and of ACTH and cortisol levels. The reciprocal changes of the ACTH and UFC levels observed in the three Cushing's patients receiving SMS suggest that the peptide may act temporarily by inhibiting glucocorticoid secretion. In view of the marked reduction of UFC recorded in 1 of the 3 Cushing's patients and in the patients with paraneoplastic Cushing's syndrome, administration of SMS seems worth trying in cases of ACTH-dependent hypercortisolism requiring medical treatment.

Original languageEnglish
Pages (from-to)275-281
Number of pages7
JournalClinical Endocrinology
Volume32
Issue number3
Publication statusPublished - 1990

Fingerprint

Octreotide
Cushing Syndrome
Somatostatin
Hydrocortisone
Adrenocorticotropic Hormone
Therapeutics
Paraneoplastic Syndromes
Pituitary ACTH Hypersecretion
Glucocorticoids
Peptides

ASJC Scopus subject areas

  • Endocrinology

Cite this

Treatment of Cushing's syndrome with the long-acting somatostatin analogue SMS 201-995 (Sandostatin). / Invitti, C.; De Martin, M.; Brunani, A.; Piolini, M.; Cavagnini, F.

In: Clinical Endocrinology, Vol. 32, No. 3, 1990, p. 275-281.

Research output: Contribution to journalArticle

@article{68b503a3045547a3b5fd86c29906ac1c,
title = "Treatment of Cushing's syndrome with the long-acting somatostatin analogue SMS 201-995 (Sandostatin)",
abstract = "Three patients with Cushing's disease and one patient with paraneoplastic hypercortisolism were treated for 24-49 days with the long-acting analogue of somatostatin, SMS 201-995, Sandoz (SMS), administered in increasing doses up to 400-1200 μg daily. In the three Cushing's patients during SMS treatment plasma ACTH displayed an initial rise and a subsequent decrease. The pattern of urinary free cortisol (UFC) tended to be opposite to that of ACTH. In one of these patients, UFC continued to decrease throughout the treatment, without becoming normal. In the patient with paraneoplastic hypercortisolism, SMS was associated with a progressive decrease, though not the normalization, of UFC and of ACTH and cortisol levels. The reciprocal changes of the ACTH and UFC levels observed in the three Cushing's patients receiving SMS suggest that the peptide may act temporarily by inhibiting glucocorticoid secretion. In view of the marked reduction of UFC recorded in 1 of the 3 Cushing's patients and in the patients with paraneoplastic Cushing's syndrome, administration of SMS seems worth trying in cases of ACTH-dependent hypercortisolism requiring medical treatment.",
author = "C. Invitti and {De Martin}, M. and A. Brunani and M. Piolini and F. Cavagnini",
year = "1990",
language = "English",
volume = "32",
pages = "275--281",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Treatment of Cushing's syndrome with the long-acting somatostatin analogue SMS 201-995 (Sandostatin)

AU - Invitti, C.

AU - De Martin, M.

AU - Brunani, A.

AU - Piolini, M.

AU - Cavagnini, F.

PY - 1990

Y1 - 1990

N2 - Three patients with Cushing's disease and one patient with paraneoplastic hypercortisolism were treated for 24-49 days with the long-acting analogue of somatostatin, SMS 201-995, Sandoz (SMS), administered in increasing doses up to 400-1200 μg daily. In the three Cushing's patients during SMS treatment plasma ACTH displayed an initial rise and a subsequent decrease. The pattern of urinary free cortisol (UFC) tended to be opposite to that of ACTH. In one of these patients, UFC continued to decrease throughout the treatment, without becoming normal. In the patient with paraneoplastic hypercortisolism, SMS was associated with a progressive decrease, though not the normalization, of UFC and of ACTH and cortisol levels. The reciprocal changes of the ACTH and UFC levels observed in the three Cushing's patients receiving SMS suggest that the peptide may act temporarily by inhibiting glucocorticoid secretion. In view of the marked reduction of UFC recorded in 1 of the 3 Cushing's patients and in the patients with paraneoplastic Cushing's syndrome, administration of SMS seems worth trying in cases of ACTH-dependent hypercortisolism requiring medical treatment.

AB - Three patients with Cushing's disease and one patient with paraneoplastic hypercortisolism were treated for 24-49 days with the long-acting analogue of somatostatin, SMS 201-995, Sandoz (SMS), administered in increasing doses up to 400-1200 μg daily. In the three Cushing's patients during SMS treatment plasma ACTH displayed an initial rise and a subsequent decrease. The pattern of urinary free cortisol (UFC) tended to be opposite to that of ACTH. In one of these patients, UFC continued to decrease throughout the treatment, without becoming normal. In the patient with paraneoplastic hypercortisolism, SMS was associated with a progressive decrease, though not the normalization, of UFC and of ACTH and cortisol levels. The reciprocal changes of the ACTH and UFC levels observed in the three Cushing's patients receiving SMS suggest that the peptide may act temporarily by inhibiting glucocorticoid secretion. In view of the marked reduction of UFC recorded in 1 of the 3 Cushing's patients and in the patients with paraneoplastic Cushing's syndrome, administration of SMS seems worth trying in cases of ACTH-dependent hypercortisolism requiring medical treatment.

UR - http://www.scopus.com/inward/record.url?scp=0025129338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025129338&partnerID=8YFLogxK

M3 - Article

C2 - 2160871

AN - SCOPUS:0025129338

VL - 32

SP - 275

EP - 281

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 3

ER -